Compare IH & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | ADAG |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 84.8M |
| IPO Year | 2020 | 2021 |
| Metric | IH | ADAG |
|---|---|---|
| Price | $2.11 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 8.2K | ★ 52.0K |
| Earning Date | 12-29-2025 | 08-12-2025 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $119,261,855.00 | $103,204.00 |
| Revenue This Year | $39.02 | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | $7.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.55 | $1.30 |
| 52 Week High | $3.60 | $3.16 |
| Indicator | IH | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 51.32 |
| Support Level | $2.15 | $1.74 |
| Resistance Level | $2.34 | $1.89 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 9.18 | 80.30 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.